Monoclonal Antibody

Pembrolizumab

Pembrolizumab is a monoclonal antibody that targets PD-1, an immune checkpoint protein.

Research Overview

PD-1 pathway research is an important area in cancer immunotherapy. Pembrolizumab is included in CHENGENE's monoclonal antibody research portfolio.

Research Enquiry ↗

CHENGENE PRIVATE LIMITED

Advancing biotechnology through research.

Contact our team for further information about CHENGENE's research and development portfolio. Product availability, development status and regulatory details should be confirmed directly with the company.